BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21674738)

  • 1. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model.
    Saito A; Morishita N; Mitsuoka C; Kitajima S; Hamada K; Lee KM; Kawabata M; Fujisawa M; Shirakawa T
    J Gene Med; 2011 Jun; 13(6):353-61. PubMed ID: 21674738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
    Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
    Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.
    Tsai V; Johnson DE; Rahman A; Wen SF; LaFace D; Philopena J; Nery J; Zepeda M; Maneval DC; Demers GW; Ralston R
    Clin Cancer Res; 2004 Nov; 10(21):7199-206. PubMed ID: 15534093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
    Toivonen R; Suominen E; Grenman R; Savontaus M
    Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus.
    Hamada K; Zhang T; Desaki J; Nakashiro K; Itoh H; Tani K; Koyama Y; Hamakawa H
    J Gene Med; 2010 Jun; 12(6):545-54. PubMed ID: 20527047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
    Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y
    Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM; Ni S; Tieu AT; Lieber A
    Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus based on serotype 3.
    Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
    Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer.
    Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J
    Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.
    Kim JH; Lee YS; Kim H; Huang JH; Yoon AR; Yun CO
    J Natl Cancer Inst; 2006 Oct; 98(20):1482-93. PubMed ID: 17047197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy.
    Hamada K; Kohno S; Iwamoto M; Yokota H; Okada M; Tagawa M; Hirose S; Yamasaki K; Shirakata Y; Hashimoto K; Ito M
    Cancer Res; 2003 May; 63(10):2506-12. PubMed ID: 12750273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.